Retatrutide 30mg
Triple-pathway GIP/GLP-1/glucagon receptor agonist research compound
Ordering is not open
PepGo is not accepting orders while its controlled pre-launch checks are in progress.
Specification
- Purity
- ≥99% (HPLC/MS)
- Size
- 30mg
- Molecular Weight
- 4,845.4 g/mol
- CAS
- 2381089-83-2
- Catalog No.
- PG-RETA-030
- Form
- Lyophilized powder
- Storage
- -20°C, protect from light
Overview
Retatrutide is a synthetic investigational peptide engineered as a triple agonist — active at three distinct receptor targets simultaneously — representing the current frontier of multi-pathway metabolic research compounds.
Mechanism
Triple-pathway GIP/GLP-1/glucagon receptor agonist research compound
Research Note
Studied in preclinical models for broad multi-system signaling from co-activating three pathways, and used as the reference point in triple- vs. dual-agonist comparative work.
References
- [1]Jastreboff A.M. et al. (2023). NEJM 389:514–526
- [2]Rosenstock J. et al. (2023). Lancet 402(10401):529–544
Research Use Only
This product is a chemical reagent for in-vitro laboratory research only. It is not for human or veterinary use, consumption, or any diagnostic or clinical application.
Storage & Handling
Storage
Store sealed at -20°C, protected from light and moisture, until laboratory use. Reseal and return to cold storage promptly after handling.
Handling
Supplied as a lyophilized powder intended for in-vitro laboratory use. Handle with standard laboratory PPE and technique appropriate to your research protocol.
Stability
Stable as a lyophilized powder under recommended storage conditions through the labeled use-by date. Post-preparation stability depends on the buffer and conditions selected by the researcher.
Frequently Asked Questions
For Research Use Only. Not for human or veterinary use. Products have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.